Phase I clinical trial results for the σ2 radioligand [18F]ISO-1 showed that [18F]ISO-1 uptake values correlated with tumor Ki-67 (a gold standard proliferation biomarker) and are expected to be used for in vivo measurement of tumor proliferation status (Dehdashti et al., 2013). Here, MKI67 is linked to neoplasm.